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INTRODUCTION
The spectrum of Candida species associated with invasive
fungal infections is evolving. New microbiology diagnostic
tools, the increasing number of immunosuppressed patients
with invasive devices and the use of prophylaxis with
fluconazole could contribute to this phenomenon (1). In
recent years, an increasing number of rare species with
reduced susceptibility to antifungal molecules have been
described, including C. ciferrii, C. inconspicua, C. guilliermon-
dii, C. humicola, C. lambica, C. lipolytica, C. norvegensis, C.
palmioleophila, C. rugosa, C. valida, C. fermentati, and C.
lusitaniae (2-5). Data from the SENTRY Antimicrobial
Surveillance Program-Fungal Objective (5) concerning
bloodstream infections from 2008 and 2009 show that 4.5%
of 348 episodes from 10 centers in Latin America were
caused by species other than C. albicans, C. glabrata, C.
parapsilosis, C. tropicalis, and C. krusei.
In 1984, Lavarde et al. (6) reported the first clinical isolate
of C. haemulonii from a blood culture. Since then, rare cases
of human infections with C. haemulonii have been reported
worldwide, including central venous catheter (CVC)-related
bloodstream infections in patients from Argentina, Korea,
and China (7-11); in preterm neonates receiving parenteral
nutrition in Kuwait (12); and in a 37-year-old French patient
with osteomyelitis of the left hallux (13). This pathogen has
not been identified in previous reports of candidemia from
Brazil (14-17).
The present paper reports for the first time a case of
fungemia caused by C. haemulonii in a tertiary hospital in the
city of Sa˜o Paulo. Clinical features and laboratory analyses,
including phenotypic and molecular identification and
antifungal susceptibility testing (AST), are described.
CASE DESCRIPTION
A 26-year-old woman diagnosed with ovarian carcinoma
with a low degree of differentiation two months before
hospitalization was admitted to the Institute of Cancer in
May 2010 for abdominal pain. The patient was submitted to
laparotomy and tumor resection. Four days later, the patient
developed fever and low back pain, and a diagnosis of
pyelonephritis was established. Piperacillin/tazobactam 4.5 g
three times per day was prescribed. Because of persistent
clinical deterioration, the antimicrobial therapy was changed
to imipenem 0.5 g four times per day and vancomycin 1 g two
times per day. After stabilization of the patient’s clinical
condition and the cessation of antibiotics, chemotherapy
comprising carboplatin and paclitaxel was started through a
CVC. In June 2010, after the second cycle of chemotherapy, the
patient was diagnosed with febrile neutropenia, and two sets
of BactecTM aerobic bottles (Becton Dickinson Diagnostics,
USA) were collected for blood cultures. Imipenem and
vancomycin were reinitiated. After two days, a provisional
analysis of the blood culture showed the presence of budding
yeast cells. Due to the poor prognosis and the lack of response
to chemotherapy, all antibiotics were stopped, and no
antifungal agent was prescribed. The patient died six days
after the positive blood culture.
Microbial growth was detected after 24 hours in Bactec
9249 incubator (Becton Dickinson Diagnostics, USA). Gram
staining of the positive blood cultures showed the presence
of yeast. The samples were seeded on CHROMagar
CandidaTM medium (Becton Dickinson Diagnostics, USA).
Pink colonies grew after 24 hours of incubation at 37 C˚.
After 72 hours, the colonies developed darker violet central
pigmentation. Further phenotypic identification was con-
ducted using API 20CTM AUX panels (BioMe´rieux, Marcy-
L’Etoile, France) but was inconclusive. A VITEK 2TM system
(BioMe´rieux, Marcy-L’Etoile, France) identified the isolate
as C. haemulonii with 97% certainty.
The DNA from the isolate was extracted as described by
Loffler et al. (18) using 250 U/mL of recombinant lyticase
(L-4276, Sigma-Aldrich, St. Louis, MO, USA) and the
QIAamp DNA Mini kit (QIAGEN, Hilden, Germany)
according to the manufacturer’s protocol. Amplification
targeted the Candida ITS sequence and was performed in a
total volume of 25 ml containing 16enzyme buffer, 200 mM
dNTPs, 0.4 mM each of the ITS1 and ITS4 primers (19),
2 mM MgCl2, 2.5 U of Taq DNA polymerase (Invitrogen,
Sa˜o Paulo, Brazil) and 5 ng of the template DNA from the
Candida isolate. The PCR was conducted in a thermocycler
(Veriti, Applied Biosystems, Carlsbad, CA, USA) with an
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initial denaturation step at 95 C˚ for 5 minutes; 30 cycles of 1
minute at 95 C˚, 1 minute at 55 C˚ and 1 minute at 72 C˚; and a
final extension at 72 C˚ for 5 minutes. The amplification
product was purified using the PureLinkTM PCR purifica-
tion kit (Invitrogen, Carlsbad, CA, USA) and sequenced
in both directions in a MegaBace-1000 analyzer (GE
Healthcare, Buckinghamshire, UK). The sequences were
compared with the reference sequences available in
GenBank using BLAST (http://blast.ncbi.nlm.nih.gov).
The results of the phenotypic and molecular analyses are
summarized in Table 1. Molecular methods confirmed the
identity of C. haemulonii.
Antifungal susceptibility testing (AST) was performed
using Sensititre YeastOneTM colorimetric plates (Trek
Diagnostic Systems, Cleveland, USA) according to the
manufacturer’s instructions, and interpretation was per-
formed according to the breakpoints established by the
Clinical Laboratory Standards Institute (CLSI) (20). The
drugs included in these panels and their concentrations
were as follows: posaconazole (0.004-8 mg/L), fluconazole
(0.125-256 mg/L), itraconazole (0.008-16 mg/L), ketocona-
zole (0.008-16 mg/L), voriconazole (0.008-16 mg/L), 5-flu-
cytosine (0.03-64 mg/L), caspofungin (0.008-16 mg/L) and
amphotericin (0.008-16 mg/L). Reference strains (C. para-
psilosis ATCC 22019 and C. krusei ATCC 6258) were used for
quality control purposes. The AST results are summarized
in Table 2. The isolate had elevated minimal inhibitory
concentrations (MICs) for amphotericin and flucytosine.
DISCUSSION
Sunyong Kim et al. (11) identified reports of C. haemulonii
bloodstream infections in the literature and summarized the
clinical characteristics of the patients who developed these
infections. These authors found that among ten cases, nine
were related to CVCs. Most isolates had elevated MICs for
amphotericin, fluconazole and itraconazole, and treatment
failure occurred when one of these drugs was prescribed
(11). Among four patients treated with an echinocandin,
only one experienced treatment failure (11).
Mi-Na Kim et al. (9) described eight cases of fungemia
caused by C. haemulonii and C. pseudohaemulonii in five
hospitals in Korea. Four of these patients had received
previous antifungal therapy, and all of the patients had a
severe underlying disease and a CVC (9).
Oh et al. (21) investigated the in vitro production of biofilms
by C. haemulonii and C. pseudohaemulonii. The formation of
biofilms reflects the potential of these two species to cause
catheter-related bloodstream infections. In accordance with
these previous reports, our patient had a severe underlying
disease and a CVC when candidemia was diagnosed.
The darker violet central pigmentation of the colonies
after 72 hours of incubation in chromogenic medium is not a
characteristic specific to C. haemulonii. Hospenthal et al. (22)
studied the appearance of 83 isolates of different Candida
species on CHROMagarTM Candida medium (CHROMagar
Microbiology, Paris, France) and found that C. glabrata also
developed darker violet pigmentation after three or four
days of incubation.
Ruan et al. (10) described three C. haemulonii infections that
were identified by VITEK 2TM and confirmed by ITS1 and 18S
rRNA sequencing. However, Mi-Na Kim et al. (9) showed that
most isolates obtained from blood cultures that are identified
as C. haemulonii by VITEK 2TM were determined to be C.
pseudohaemulonii based on the sequences of D1/D2 regions of
the rRNA gene. These authors also reported that these two
species are closely related according to phylogenetic analysis
(9). Genotypic identification of the present isolate by ITS
sequencing showed 100% identity with C. haemulonii but only
94% identity with C. pseudohaemulonii, thus confirming the
identification of our isolate as the former species according to
the CLSI MM-18A guidelines (23). Fluconazole, caspofungin,
voriconazole, and posaconazole showed good in vitro activity.
According to other reports, most isolates of C. haemulonii
related to candidemia are resistant to amphotericin and
fluconazole (10). Table 3 summarizes the antifungal suscept-
ibility profile of C. haemulonii isolates from Argentina, Korea,
Kuwait, China, and Brazil.
To our knowledge, this is the first report of a clinical isolate
of C. haemulonii in Brazil. VITEK2TM correctly identified the
etiologic agent, but DNA sequencing was necessary for final
identification. Echinocandins and voriconazole should be
empirical treatment options when C. haemulonii infection is
suspected and an antifungigram is not available.
Table 1 - Identification of Candida haemulonii by two commercial biochemical systems and by sequencing analysis.
VITEK 2 (%ID*) API 20AUX (%ID*) ITS sequencing alignment score (%ID*)
ITS 1 Forward ITS 4 Reverse
97%
C. haemulonii
52.2%
C. parapsilosis
34.2 %
C. guilliermondii
13.1%
C. famata
100%
C. haemulonii**
94%
C. pseudohaemulonii#
100%
C. haemulonii**
94%
C. pseudohaemulonii#
*:Percentual identification given; **:CBS6915 – GenBank access number AB118790;
#: GenBank access number EU881976.1
Table 2 - Antifungal susceptibility profile of Candida
haemulonii determined using a Sensititre YeastOneTM
panel.
Drug MIC (mg/L)
CLSI Interpretation
(M23-A3)
Amphotericin 4 *
Fluconazole 8 S
Itraconazole 0.25 SDD
Voriconazole 0.064 S
Caspofungin 0.25 S
Posaconazole 0.125 **
Flucytosine 64 R
S: susceptible; SDD: susceptible dose dependent; R: resistant; *: likely
resistant when MIC.1 mg/l, **: breakpoints not established by CLSI.
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Table 3 - Comparison of the antifungal susceptibility of Candida haemulonii bloodstream isolates according to author
and the year of publication.
Author
Year of
Report Country Isolate MIC (mg/L)/Antifungal Susceptibility Profile*
AMB** FLU VOR CAS ITRA
Rodero et al. (7). 2002 Argentina 1 4 32/S-DD NT NT 0.12/S
Giusiano et al. (8). 2006 Argentina 1 1 32/S-DD NT NT MD/R
Khan et al. (12). 2007 Kuwait 1 4 96/R 0.047/S 0.5/S 2/R
2 6 .256/R 0.125/S 0.023/S 3/R
3 4 .256/R 0.125/S 0.125/S 2/R
4 8 .256/R 0.125/S 0.125/S 4/R
Mi-Na Kim et al. (9). 2009 Korea 1 1 64/R 1/S 0.125/S 4/R
Ruan et al. (10). 2010 China 1 2 16/S-DD 0.25/S 1/S 0.25/S-DD
2 2 16/S-DD 0.25/S 1/S 0.25/S-DD
Sunyong Kim et al. (11). 2010 Korea 1 0.5 8/S 0.5/S 0.125/S 0.25/S-DD
Almeida Junior et al. (our
case). 2012 Brazil 1 4 8/S 0.064/S 0.25/S 0.25/S-DD
MIC: minimal inhibitory concentration; AMB: amphotericin B; FLU: fluconazole; VOR: voriconazole; CAS: caspofungin; ITRA: itraconazole; *interpretation
according to CLSI breakpoints document M27; **likely resistant if MIC.1 mg/L; S: susceptible; S-DD: susceptible dose dependent; R: resistant; NT: not
tested; MD: missing data.
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